AI Tool Predicts Which Peptides Will Trigger Immune Responses for Cancer Vaccines

Developed a multimodal recurrent neural network (MARIA) trained on: (1) in vitro HLA binding measurements, (2) mass spectrometry-identified peptide-HLA ligand sequences, (3) antigen gene expression levels, and (4) protease cleavage signatures. Performance evaluated on validation datasets and independently validated against published cancer neoantigen studies measuring CD4+ T cell responses.

Predicting which peptide fragments the immune system will recognize is the fundamental challenge in designing cancer vaccines and immunotherapies. HLA class II presentation to CD4+ T cells is critical for sustained immune responses but has been much harder to predict than HLA class I. MARIA's superior accuracy — published in Nature Biotechnology — could accelerate personalized cancer vaccine development by identifying the most promising peptide targets from a patient's tumor.

Personalized cancer vaccines are one of the most promising frontiers in oncology, but their success depends on accurately predicting which tumor peptides will activate the patient's immune system. MARIA represents a step change in HLA class II prediction, which has lagged behind HLA class I tools. As AI and immunogenomics converge, tools like MARIA could become standard in the clinical pipeline for designing individualized cancer immunotherapies.

Prediction accuracy, while best-in-class, is not perfect (AUC 0.89–0.92). Performance may vary across less common HLA alleles with fewer training examples. The tool predicts antigen presentation, not guaranteed immune response — other factors affect whether a presented peptide actually triggers effective immunity. Computational predictions always require experimental validation.